Jump to main content
Jump to site search


New amyloid beta-disaggregating agents: Synthesis, pharmacological evaluation, crystal structure and molecular docking of N-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl) amines

Abstract

In the journey towards the development of potent multi-targeted ligands for the treatment of Alzheimer's disease, a series of Aβ aggregation inhibitors having Quinoline scaffold were designed utilizing computational biology tools, synthesized and characterized by various spectral techniques including single-crystal X-ray crystallography. Organic synthesis relying upon convergent synthetic routes were employed. Investigations via ThT fluorescence assay, electron microscopy and transmission electron microscopy revealed the synthesized derivatives to exhibit Aβ self-aggregation inhibition. Molecules 5g and 5a showed highest inhibitory potential, 53.73% and 53.63% at 50 μM respectively; higher than the standard Aβ disaggregating agent, Curcumin. Molecules 5g and 5a disaggregated AChE-induced (58.26%, 47.36%) Aβ aggregation more than two folds than that of standard drug-Donepezil (23.66%) and inhibited Cu2+-induced Aβ aggregation. Docking study significantly showed their interaction with key residues of Aβ and the results were in accordance with study. Besides, these compounds also exhibited potential antioxidant activity (5a, 2.7240 trolox equivalent by ORAC assay) and metal chelating property. Furthermore, the stoichiometric ratio of Cu(II)-5a and Cu(II)-5g complex es were found by Job’s method (0.5:1 for 5a and 0.8:1 for 5g). In silico ADMET profiling showed these derivatives to have drug like properties with very low toxic effects in the pharmacokinetic study. Overall, these results displayed a composed profile with promising Aβ aggregation inhibition and antioxidation and metal chelation activity that could be helpful for developing new multifunctional agents against Alzheimer’s disease.

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Jun 2018, accepted on 06 Aug 2018 and first published on 20 Aug 2018


Article type: Research Article
DOI: 10.1039/C8MD00312B
Citation: Med. Chem. Commun., 2018, Accepted Manuscript
  •   Request permissions

    New amyloid beta-disaggregating agents: Synthesis, pharmacological evaluation, crystal structure and molecular docking of N-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl) amines

    T. umar, S. Shalini, K. Raza, S. Gusain, J. Kumar, W. Ahmed, M. Tiwari and N. Hoda, Med. Chem. Commun., 2018, Accepted Manuscript , DOI: 10.1039/C8MD00312B

Search articles by author

Spotlight

Advertisements